Cytokinetics should hear back from the FDA ... The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most respected events for bio & pharmaceutical manufacturing ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team ...

The Food and Drug Administration is expected to decide in late September whether to approve Cytokinetics' first drug, the heart failure medicine aficamten. Brett Pletcher, who in August joined ...

NASDAQ CYTK opened at $39.48 on Tuesday. The stock has a market cap of $4.71 billion, a P/E ratio of -7.34 and a beta of 0.94. Cytokinetics has a fifty-two week low of $32.74 and a fifty-two week ...

SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 15, 2025 it granted stock options to purchase an aggregate ...

View Our Latest Stock Analysis on Cytokinetics Cytokinetics Stock Performance CYTK opened at $43.19 on Monday. Cytokinetics has a 52-week low of $40.53 and a 52-week high of $75.71. The company ...